Melanoma is eminently curable if primary tumors are detected at an early stage and surgically removed. Because of this, monitoring of high-risk patients and of pre-malignant lesions such as dysplastic nevi is frequently recommended. However, a high proportion of melanomas arise de novo and not in association with previously benign nevi (Weatherhead et al., 2007) . Because of this, not all primary melanomas present at a stage that is reliably curable by surgery, and over 10% of patients present with metastatic disease . Therefore, despite the importance of understanding melanomagenesis to improve primary prevention, appreciating how melanomas propagate after the establishment of a primary 
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Melanoma, like most cancers, is a disease that wreaks havoc mostly through its propensity to spread and establish secondary tumors at sites that are anatomically distant from the primary tumor. The consideration of models of cancer progression is therefore important to understand the essence of this disease. Previous work has suggested that melanoma may propagate according to a cancer stem cell (CSC) model in which rare tumorigenic and bulk non-tumorigenic cells are organized into stable hierarchies within tumors. However, recent studies using assays that are more permissive for revealing tumorigenic potential indicate that it will not be possible to cure patients by focusing research and therapy on rare populations of cells within melanoma tumors. Studies of the nature of tumorigenic melanoma cells reveal that these cells may gain a growth, metastasis and/or therapy resistance advantage by acquiring new genetic mutations and by reversible epigenetic mechanisms. In this light, efforts to link the phenotypes, genotypes and epigenotypes of melanoma cells with differences in their in vivo malignant potential provide the greatest hope of advancing the exciting progress finally being made against this disease.
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Melanoma progression
Melanoma is eminently curable if primary tumors are detected at an early stage and surgically removed. Because of this, monitoring of high-risk patients and of pre-malignant lesions such as dysplastic nevi is frequently recommended. However, a high proportion of melanomas arise de novo and not in association with previously benign nevi (Weatherhead et al., 2007) . Because of this, not all primary melanomas present at a stage that is reliably curable by surgery, and over 10% of patients present with metastatic disease . Therefore, despite the importance of understanding melanomagenesis to improve primary prevention, appreciating how melanomas propagate after the establishment of a primary
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tumor is critical to reduce the physical and economic burden of this disease. Conceptually, cancer propagation is proposed to occur according to various models, each of which provides an independent explanation of the phenotypic and functional heterogeneity that is often apparent among cells within a malignant tumor. The first is the cancer stem cell (CSC) model (Dick, 2008; Lobo et al., 2007; Reya et al., 2001) , in which tumor growth is primarily driven by rare populations of highly tumorigenic cells that not only renew their own malignant potential, but also give rise to bulk populations of other cells that are irreversibly less-and/or non-tumorigenic. Second is the clonal evolution model (Fearon and Vogelstein, 1990; Foulds, 1958; Lengauer et al., 1998; Nowell, 1976) , in which a high proportion of cells in a cancer has the potential to drive disease progression and in which certain cells acquire additional genetic mutations that provide an advantage in growth and/or metastasis capability. More recently, the separate notion of cancer cell plasticity, or interconversion, has been increasingly recognized in the literature as contributing to cancer cell heterogeneity and progression of malignant disease (Gupta et al., 2009; Mani et al., 2008; Marusyk and Polyak, 2010; Pinner et al., 2009; Roesch et al., 2010; Sharma et al., 2010) . The interconversion model refers to reversible switching of cancer cells between more and less actively malignant behaviors that may be associated with phenotypic distinctions and differences in therapy responsiveness between cells. In fact, although these models are conceptually quite different, they are not mutually exclusive, and it is likely that at least some cancers use more than one of these models at different stages, or even simultaneously, during their evolution in a patient (Marusyk and Polyak, 2010; Shackleton, 2010) .
How does melanoma progress? From a clinical perspective, melanoma is generally considered to be a highly aggressive cancer, although a small subset of patients with metastatic melanoma has a relatively indolent disease course (Tsao et al., 2004) . Histologically, mitoses are frequently apparent in sections of melanoma tumors and staining for proliferative markers such as Ki67 is usually positive (Ohsie et al., 2008) . In this light, it would be surprising if melanoma progressed according to a model in which tumorigenic cells were rare. However, cellular heterogeneity is also a histological feature of many melanomas, and studies of cell surface marker expression indicate that multiple, phenotypically distinct subpopulations of melanoma cells exist within tumors (Fang et al., 2005; Quintana et al., 2008; Schatton et al., 2008) .
The basis of this heterogeneity has been the subject of intense debate among melanoma biologists e and rightfully so. If melanoma cell heterogeneity develops in the context of a CSC model, then separate identification, study and therapeutic targeting of the rare tumorigenic cell population should result in great clinical benefit to patients. Furthermore, studying melanoma tumors as a whole is likely to mask the critical drivers of melanoma progression if these drivers are only present in a rare minority of the cells. However, if a high proportion of melanoma cells has tumorigenic potential and is subject to ongoing and extensive genetic and/or epigenetic change, the implications for managing this disease would be profound. For example, targeting single oncogenic mechanisms to which tumors are supposedly 'addicted' (Weinstein and Joe, 2008) may be only fleetingly beneficial in genetically unstable melanomas in which resistance mechanisms rapidly emerge. Similarly, cancer cells that are able to avoid therapeutic intervention by transiently switching to epigenetically-determined states of resistance may require a multipronged treatment approach (Sharma et al., 2010 in this study no differences in two-dimensional adherent growth were seen between cells according to expression of CD133, indicating that culture conditions can affect the evaluation of clonogenicity in melanoma cells. An important question arising from these studies is whether the cells that were not clonogenic in vitro were tumorigenic in vivo. Tumorigenicity, a key component of malignant behaviour, is a property of cancer cells that by definition can only be demonstrated in vivo. Although clonogenic potential must exist in a cell for tumor formation to occur, it is not known how well the normal in vivo environment that supports clonogenic tumor growth in patients is recapitulated in vitro. In fact, melanoma cells isolated from patients are often difficult to grow in culture, despite displaying overt tumorigenicity. We have tested melanoma cells purified from six tumors obtained from patients with metastatic disease for their ability to form colonies in culture conditions that we have found to be supportive of melanoma cell growth (Fig. 1a) . Each melanoma contained a high proportion (13%e70%) of cells with tumorigenic potential when evaluated in immunocompromised NOD/SCID IL2Rg À/À (NSG) mice, a highly permissive model for this purpose (Quintana et al., 2008) . However, only four of these melanomas contained cells that proliferated and formed colonies in non-adherent culture. In three experiments, we also cultured cells adherently after plating on tissue culturetreated plastic (adherent culture on Matrigel did not increase the detectable frequency of clonogenic cells compared to culture on plastic; data not shown). Although the frequency of detectable clonogenic cells was generally higher in adherent culture than in non-adherent culture (Fig. 1a) , in most cases the proportion of colony-forming cells identified in any culture condition was several-fold lower than the proportion of tumor-forming cells identified in NSG mice (Fig. 1a) . Notably, when we used limiting dilution analysis to calculate the frequency of cells in each culture condition that were tumorigenic in vivo, no significant differences were apparent between cells cultured adherently or non-adherently ( Fig. 1bed ). Although these latter experiments were performed using suboptimal tumorigenesis assays (NOD/SCID mice without Matrigel) and the observations need to be confirmed in more permissive assays (NSG mice with Matrigel), the data suggest that in comparison with adherent culture, non-adherent culture does not enhance the maintenance of tumorigenic melanoma cells. We thus find that in vitro clonogenicity is an inadequate surrogate for melanoma cell tumorigenicity, at least in commonly used culture conditions. The development of in vitro assays that reliably predict in vivo malignant potential of melanoma cells is a high priority in melanoma research.
Other studies have tested directly the tumorigenicity of phenotypically distinct human melanoma cells using in vivo tumorigenesis assays. The approach in these studies is appealing because cells were isolated and transplanted directly from tumors, without an intervening in vitro culture step.
Because of this, artificial changes in malignant potential that may be induced in cancer cells through extended ex vivo manipulation are minimized. Indeed, the tremendous progress and enthusiasm in the CSC field over the last 10e15 years can be largely attributed to the development of immunocompromised mouse models that permit the growth of human cancer cells obtained directly from patient tumors. Monzani et al. (2007) found that CD133 expression was associated with increased tumorigenicity in cells isolated directly from seven metastatic patient tumors and evaluated by transplantation into immunocompromised NOD/SCID mice. In this study, injection of CD133 þ cells produced tumors in the mice after only 40e50 days, whereas no tumors arose from CD133 À cells after 4 months. Similarly, Schatton et al. (2008) identified a subpopulation of human melanoma cells that was characterized by expression of the multidrug transporter molecule ABCB5 and by enriched tumorigenicity in NOD/SCID mice. In this study, the empirically determined overall frequency of tumorigenic cells in the melanomas studied was approximately 1 in a million, and the tumorigenic cell frequency (Quintana et al., 2008) . Cells from the same tumors were also grown in vitro non-adherently (using ultra-low binding 6-well plates (Corning)) and in some cases adherently (using tissue culture-treated 6-well plates (Corning)) at clonal density using otherwise identical culture conditions (6.5% CO2) and media (50% DMEM-low, 30% Neurobasal (Invitrogen), 15% CEE (Stemple and Anderson, 1992) , 1% Pen/ Strep, 1% non-essential amino acids (Gibco), 117 nM retinoic acid, 50 mM 2-mercaptoethanol, (Sigma), 1% N2 supplement, 2% B27 supplement (Gibco), 20 ng/mL recombinant human bFGF, 20 ng/mL IGF-1 (R&D systems)). In vitro clonogenicity is shown as the mean (±s.d.) percentage of plated cells that formed colonies in either culture condition (percentages derived from up to four independent experiments per melanoma, each one including cells plated into three separate wells). In some experiments, cells were cultured side-by-side either on tissue culture-treated plastic or after embedding cells in 25% Matrigel. No significant differences were observed in the frequency of clonogenic cells identified in either of these adherent culture conditions (data not shown). The frequency of clonogenic cells identified in vitro was in every case lower than the empirically determined tumorigenic cell frequency in NSG mice. In two melanomas (205 and 308) that displayed robust tumorigenicity in NSG mice, melanomaspheres could not be generated at all and adherent colony formation was poor. Overall, in vitro clonogenicity was a poor surrogate for in vivo tumorigenicity in these experiments. in the ABCB5 þ subpopulation was nearly 10-fold higher. Importantly, targeting of ABCB5 þ cells with monoclonal antibodies inhibited tumor growth in xenograft melanoma models, highlighting the potential of identifying and targeting rare tumorigenic cells in cancer therapy. Collectively, these studies suggested that melanoma could propagate according to a CSC model in which tumorigenic cells were rare and gave rise to phenotypically distinct non-tumorigenic cells in a stable and hierarchical manner.
Evidence that melanoma does not follow a cancer stem cell model
However, other studies of melanoma cell tumorigenicity suggest that this may not be the case. In light of reports that raised questions about the effects of xenotransplantation on the detection of human cell tumorigenicity by showing that tumorigenic cells were not rare in syngeneic transplantation studies of mouse cancers (Kelly et al., 2007; Williams et al., 2007) , we decided to re-evaluate the human melanoma tumorigenesis assay. These experiments revealed three parameters that affected the ability of human melanoma cells to form tumors in immunodeficient mice: 1) assay duration, 2) the degree of immunodeficiency in recipient mice, and 3) the immediate extracellular environment into which melanoma cells are transplanted. When we altered the tumorigenesis assay to include a longer post-transplant monitoring time, the use of NSG mice as recipients, and pre-embedding cells in Matrigel prior to transplantation, we observed a roughly 5000-fold increase in the ability to detect tumorigenic melanoma cells compared with published assay conditions (Quintana et al., 2008) . In a series of extended experiments evaluating in these modified assay conditions cells obtained directly from six patients with metastatic melanoma, the average frequency of tumorigenic cells was 25% (Quintana et al., 2008) . The simplest interpretation of these experiments is that metastatic melanoma contains a high proportion of cells with intrinsic tumorigenic potential that are not apparent when tumorigenicity is evaluated in assays less permissive for allowing tumor formation.
Since then, others have also found clonogenicity and/or tumorigenicity to be present in a high proportion of melanoma cells. Prasmickaite et al. (2010) demonstrated that a high proportion of melanoma cells in established cultures could be clonogenic. Zhong et al. (2010) found that >10% of cells in the B16-F10 mouse melanoma cell line were tumorigenic in the context of syngeneic transplantation. Held et al. (2010) found tumorigenicity to be a common property of melanoma cells in different mouse models. Notably in this study, single cells isolated from the large CD34 þ fraction of tumors carrying an activated BRAF mutation and lacking the tumor suppressor PTEN formed a tumor in every case (six secondary tumors arose from six CD34 
The NSG tumorigenesis assay
Could the NSG tumorigenesis assay overestimate tumorigenic potential in melanoma cells? We believe not, as by definition potential can never be overestimated, only concealed. It is highly unlikely that non-tumorigenic melanoma cells were rendered tumorigenic by exposure to Matrigel or the subcutaneous tissues of NSG mice, as the same assay conditions did not transform normal human melanocytes (Quintana et al., 2008) . Therefore, the transplanted cells that formed tumors must have harbored an intrinsic potential to do so. During neoplastic transformation a cell acquires malignant potential, including the capacity for tumor formation. In a patient, this potential may not be apparent in every cell at every moment. For example, some cells may be actively proliferating and others dormant, in part regulated by environmental influences. However, the non-proliferating cells can be said to harbor tumorigenic potential if in a different circumstance they proliferate actively and contribute to tumor formation. In a conceptually similar way, a cancer cell may still have tumorigenic potential, even if a particular assay does not reveal it. This can be shown if other assay conditions allow that same cell to form tumors. We contend that the NSG tumorigenesis assay does not make melanoma cells tumorigenic. Rather, it reveals tumorigenic potential that is already present in cells but can be hidden in other assays. Of course, not every cell with tumorigenic potential will contribute to melanoma progression in a patient. Tumorigenic potential in some melanoma cells may be transiently or permanently suppressed in patients by cell-extrinsic mechanisms, such as anti-tumor immune effects or metabolic insufficiency. Some cells may even be killed by these mechanisms. Additionally, tumorigenic potential could be irreversibly lost in some cells through cell-intrinsic mechanisms, such as stable epigenetic changes (as proposed in the CSC model) or the acquisition of deleterious genetic changes (that could occur in the context of clonal evolution). In a patient, it is not possible to test which cells with tumorigenic potential will and will not propagate disease, as in vivo studies of syngeneic human melanoma cell transplantation are not ethical. Therefore, a cell that is demonstrated to be intrinsically tumorigenic in any assay system should be considered to be potentially tumorigenic in a patient. It is not safe to ignore in therapy cancer cells that are non-tumorigenic only under certain assay conditions.
A further question arising from our studies of melanoma cell tumorigenicity in NOD/SCID and NSG mice regards the potential role of natural killer (NK) cell function in modifying the course of melanoma progression in patients. NSG mice differ from NOD/SCID mice in being depleted of NK cell function (Shultz et al., 2005) . In side-by-side assays comparing directly melanoma cell tumorigenicity in NOD/SCID vs NSG mice, we found up to over 100-fold increase in the frequency of tumorigenic cells in the NSG model (Quintana et al., 2008) . This suggests a critical role for NK cells in inhibiting the tumorigenicity of human melanoma cells in NOD/SCID mice. However, care must be taken in extrapolating these results to the ways in which NK cells in patients may limit human melanoma progression. The xenogeneic immune response in NOD/SCID mice against human melanoma cells is likely to be fundamentally different to the immune response mounted by patients against their own melanoma. NK cells may be important in the xenogeneic rejection of transplanted cells (Yang and Sykes, 2007) , but strong evidence of dominant NK cell-mediated anti-tumor effects in patients, equivalent to the elimination of the vast majority of transplanted human melanoma cells we observed in NOD/SCID mice, is lacking (Wallace and Smyth, 2005) . Efforts to understand and enhance NK cell killing of cancer cells in patients are clearly worthwhile, but our experience comparing human melanoma cell tumorigenesis in NSG and NOD/SCID mice does not necessarily justify them.
The nature of tumorigenic melanoma cells
If melanoma does not follow a cancer stem cell model characterized by rare tumorigenic cells, a fundamental question then arises as to how the disease grows and spreads with such frequently lethal rapidity in patients. Specifically, to what degree do interconversion and clonal evolution play a role in determining the nature of the large and highly malignant tumorigenic cell component of these cancers? Currently, the answers to these questions are unknown. However, evidence exists that both models of cancer progression may be relevant to understanding the mechanisms that drive melanoma propagation. For interconversion, there is evidence that melanoma cells can display plasticity. For example, phenotypic (Bennett, 1983) and functional (Hoek et al., 2008) switching of melanoma cells between different states of cell pigmentation and proliferation, respectively, has been described. Expression of Brn-2, a mediator of melanocyte differentiation through its repressive effects on MITF, was observed by intra-vital imaging to be heterogeneously and transiently present in transplanted tumors derived from the B16 mouse melanoma cell line, and associated with reduced pigmentation and increased cell invasiveness (Pinner et al., 2009 ). JARID1B, which modulates chromatin structure via demethylase activity at histone 3 K4, was found to be heterogeneously and reversibly expressed in melanoma cell lines in a way that correlated with an enhanced ability to support long-term tumorigenesis (Roesch et al., 2010) . Our own studies of expression of the cell surface marker CD133 have identified heterogeneous expression in some melanomas. In contrast to other cancers (O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004) , we have found no evidence that this marker is enriched in tumorigenic melanoma cells (Quintana et al., 2008) . Additionally, when we evaluated CD133 expression in secondary tumors derived from purified CD133 À or CD133 þ cells, similarly heterogeneous expression was seen in all tumors irrespective of their cellular origin (Shackleton et al., 2009 ). This indicates that expression of CD133 is not a heritable trait of melanoma cells in tumors, but rather determined as a result of reversible factors. A high priority in melanoma research is to understand the functional significance of melanoma cell interconversion and its relationship to transitory changes in the malignant behaviour of cells. For clonal evolution, there is evidence that heterogeneous genetic changes can evolve within a melanoma tumor. For example, sampling of multiple and separate intratumoral regions identified frequent differences in the genomic regions evaluated (Takata et al., 2000) . A critical question that arises from this observation regards the functional significance of the development of such genetic heterogeneity; which genetic changes in cells cause changes in malignant potential? One example is the amplification in chromosome 13 identified as a driver of the spontaneous development of metastatic capability in some melanoma cells through resultant overexpression of NEDD9 (Kim et al., 2006) . Another implication of the effects of genetic instability in melanoma cells is the possibility that additional genetic mutations may confer resistance to therapy, a phenomenon described in other cancers (Edwards et al., 2008; Sakai et al., 2008; Shah et al., 2007) . The clinical importance of this was further highlighted by the identification of concurrent oncogenic mechanisms that could switch mutant BRAF-driven cells from a state of sensitivity to BRAF-inhibition to a state whose malignant behaviour is enhanced by BRAF-inhibition (Heidorn et al., 2010) . Clonal evolution likely plays an important role in determining the outcome of melanoma in patients. For this reason, determining the degree and rate of genetic change among melanoma cells is also a high priority in melanoma research, particularly efforts to identify those genetic changes that drive the acquisition of enhanced malignant potential or therapy resistance.
Conclusion
Significant progress has been made in understanding the mechanisms through which established melanomas progress. This has led to the recent development of arguably the most exciting potential advance in therapy yet seen in this disease, BRAF-inhibition (Flaherty et al., 2009) , for which definitive clinical trials are currently underway. However the identification of resistance mechanisms to BRAF inhibitors (Emery et al., 2009 ) and the fact that many melanomas do not carry suitable mutations (Davies et al., 2002) indicate that much work remains to be done in understanding the nature of melanoma propagation. While the CSC model offers hope for improved treatment of some cancers by focusing research and therapies at rare populations of tumorigenic cells, it is apparent that not all cancers follow a CSC model. Although evidence from earlier studies suggested that melanoma might follow a CSC model, recent studies in more permissive tumorigenesis assays argue strongly against this possibility. Effective treatments for melanoma will thus have to account for the fact that a high proportion of cells must be eliminated. The focus of research efforts needs to be firmly on unraveling the mechanisms that promote growth, metastasis and therapy evasion in the cells with tumorigenic potential that are so abundant in this disease.
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Note added in proof
As this review was going to press, a publication from Weissman and colleagues appeared in Nature claiming to identify enriched tumorigenic capacity in the CD271/NGFR/p75 þ subfraction of human melanoma cells (Boiko et al., 2010) . In the central experiments of the paper, the authors purified melanoma cells from patient tumors (5/6 of the tumors studied were metastatic lesions -see Supp Tables 2 and 3 ) before performing intradermal transplants of cells into immunocompromised Rag2
mice. In transplants of unfractionated cells from three tumors, large numbers (!1000) of cells were generally required to generate tumors. Using limiting dilution analysis of the data (Hu and Smyth, 2009) , the maximum frequency of tumorigenic cells in unfractionated populations in any tumor was 1/2270 (95% confidence interval 1/550 -1/9,400, Supp Table 3 , tumor 213). This contrasts starkly with our studies of six melanomas obtained directly from patients in which the minimum frequency of tumorigenic cells in unfractionated populations was 1/6 (95% confidence interval 1/2 -1/15) (Quintana et al., 2008, Fig 3c, tumors 487, 491 and 498) . Furthermore, although Boiko et al. found that in 5/6 melanomas studied there was statistically significant (p<0.05) enrichment of tumorigenic potential in the CD271/NGFR/p75 þ fraction, our own studies of melanoma cells separated according to CD271/NGFR/p75 þ expression and transplanted in more permissive tumorigenesis assay conditions have not revealed a similar effect (unpublished). The reasons for these differences are not clear, but are likely related to differences in the tumorigenesis assays used (different tumor digestion protocols, different recipient mice, different injection sites). It will be important for melanoma biologists to evaluate independently these results by carefully reproducing the experimental conditions used in each study. Regardless, studies of the nature and regulation of tumorigenic melanoma cells hold the best hope of revealing new therapeutic strategies to combat this disease.
